Ross Moat - 01 Apr 2025 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Role: CHIEF COMMERCIAL OFFICER
Signature: /s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol: KNSA
Transactions as of: 01 Apr 2025
Net transactions value: -$21,422
Form type: 4
Filing time: 03 Apr 2025, 17:06:20 UTC
Previous filing: 19 Mar 2025
Next filing: 09 Apr 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KNSA	Class A Ordinary Share	Options Exercise		+1,611	+6.8%		25,167	01 Apr 2025	Direct	F1
transaction	KNSA	Class A Ordinary Share	Options Exercise		+1,741	+6.9%		26,908	01 Apr 2025	Direct	F1
transaction	KNSA	Class A Ordinary Share	Tax liability	$10,297	-473	-1.8%	$21.77	26,435	01 Apr 2025	Direct
transaction	KNSA	Class A Ordinary Share	Tax liability	$11,124	-511	-1.9%	$21.77	25,924	01 Apr 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KNSA	Share Option	Award	$0	+39,364		$0.000000	39,364	01 Apr 2025	Class A Ordinary Share	39,364	$21.77	Direct	F2
transaction	KNSA	Restricted Share Unit	Award	$0	+9,828		$0.000000	9,828	01 Apr 2025	Class A Ordinary Share	9,828		Direct	F1, F3
transaction	KNSA	Performance Share Unit	Award	$0	+19,657		$0.000000	19,657	01 Apr 2025	Class A Ordinary Share	19,657		Direct	F4, F5
transaction	KNSA	Restricted Share Unit	Options Exercise	$0	-1,611	-33%	$0.000000	3,222	01 Apr 2025	Class A Ordinary Share	1,611		Direct	F1, F6
transaction	KNSA	Restricted Share Unit	Options Exercise	$0	-1,741	-25%	$0.000000	5,221	01 Apr 2025	Class A Ordinary Share	1,741		Direct	F1, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F2	The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2025.
F3	The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2025.
F4	Each Performance Share Unit (PSU) represents a contingent right to receive a number of Class A Ordinary Shares of the Issuer based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee.
F5	Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Ordinary Share of the Issuer no later than January 30, 2028, unless such date falls on a non-business date, in which case the next business date shall apply.
F6	The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023.
F7	The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2024, and each yearly anniversary thereafter.